AlectorALEC +0.25%30 3-Year ROIIC % is 28.86 as of Dec. 2025, which is at its 10-year median of 28.86. GuruFocus rates ALEC with a GF Score™ of 30/100 and a GF Value™ of $0.73 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,323 Biotechnology companies, Alector ranks better than 68.1% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Alector's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 28.86%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Alector's 3-Year ROIIC % or its related term are showing as below:
ALEC's 3-Year ROIIC % is ranked better than 68.1% of 1323
companies
in the Biotechnology industry
Industry Median: -4.82
vs ALEC: 28.86
Alector (NAS:ALEC) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Alector 3-Year ROIIC % Related Terms
Alector 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Alector's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALEC vs TNXP, IMUX, WHWK: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Alector's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alector 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alector's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Alector's 3-Year ROIIC % falls into.
Alector's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -156.007 (Dec. 2025) - -137.834 (Dec. 2022) )
/
( 67.281 (Dec. 2025) - 130.261 (Dec. 2022) )
=
-18.173
/
-62.98
=
28.86%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Alector (ALEC) has a 3-Year ROIIC % of 28.86 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Alector and its competitors. This is near median its historical median of 28.86. According to the industry distribution chart, Alector ranks #422 out of 1323 companies in the Biotechnology industry, placing it in the top 31.9%.
Is Alector's 3-Year ROIIC % too high?
Alector's current 3-Year ROIIC % of 28.86 is near median its 10-year median of 28.86. Based on the distribution chart, Alector ranks #422 out of 1323 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alector has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alector's 3-Year ROIIC % compare to TNXP and IMUX?
According to the Biotechnology industry distribution chart, Alector ranks #422 out of 1323 companies for 3-Year ROIIC %. This puts Alector in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Alector and its competitors. Alector's current 3-Year ROIIC % is 28.86, which is near median its own 10-year median of 28.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alector stock overvalued right now?
Based on GuruFocus' analysis, Alector (ALEC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.73, compared to a current price of $2.01 — trading 175.3% above its estimated fair value. The current 3-Year ROIIC % is 28.86, which is near median its 10-year median of 28.86. Alector's overall GF Score™ is 30/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Alector (ALEC), the current 3-Year ROIIC % is 28.86 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alector (ALEC) Overvalued in 2026?
Based on GuruFocus' analysis, Alector stock appears to be overvalued.
The current stock price of $2.01 is trading 175.3% above its estimated GF Value™ of $0.73.
GuruFocus considers Alector to be Significantly Overvalued.
Key valuation signals for ALEC:
3-Year ROIIC %: 28.86 (near median its 10-year median of 28.86)
GF Value™: $0.73 vs. price of $2.01 (175.3% above fair value)
No single metric tells the full story. See the ALEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
30GF Score
Get the complete analysis for ALEC
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALEC has been successfully added to your 
